Invention Grant
- Patent Title: Heterocyclic compounds
-
Application No.: US16753630Application Date: 2018-10-04
-
Publication No.: US11447488B2Publication Date: 2022-09-20
- Inventor: Tomoaki Hasui , Shinji Nakamura , Satoshi Mikami , Tohru Yamashita
- Applicant: Takeda Pharmaceutical Company Limited
- Applicant Address: JP Osaka
- Assignee: Takeda Pharmaceutical Company Limited
- Current Assignee: Takeda Pharmaceutical Company Limited
- Current Assignee Address: JP Osaka
- Agency: Finnegan, Henderson, Farabow, Garrett & Dünner, LLP
- Priority: JPJP2017-195906 20171006
- International Application: PCT/JP2018/037283 WO 20181004
- International Announcement: WO2019/070044 WO 20190411
- Main IPC: C07D471/04
- IPC: C07D471/04 ; C07D407/12 ; C07D413/10 ; C07D413/14

Abstract:
The present invention aims to provide a heterocyclic compound having an AMPA receptor potentiator effect, which is expected to be useful as an agent for the prophylaxis or treatment of depression, Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like.
The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.
The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.
Public/Granted literature
- US20200247801A1 HETEROCYLIC COMPOUNDS Public/Granted day:2020-08-06
Information query